| Статус: | Recruiting |
| Фаза: | не указано |
| Начало: | 2 апреля 2025 г. |
| Окончание: | 12 сентября 2028 г. |
| Описание: | This real-world clinical trial evaluates the effectiveness of semaglutide (target dose is 2.4 mg/week) over 154 weeks (3 years) prescribed to the patients with metabolic dysfunction-associated fatty liver disease (MAFLD) and liver fibrosis (stages 0-4) as a part of routine clinical practice. MAFLD is a common liver condition linked to obesity, type 2 diabetes (T2DM), and metabolic syndrome, which can progress to severe liver damage (cirrhosis) and heart disease. Currently, there are no approved medications for MAFLD, and treatment relies on lifestyle changes. Semaglutide, a GLP-1 receptor agonist, has shown promise in improving liver health and metabolic markers in earlier studies. |
| смотреть на ClinicalTrials.gov |
| Статус: | Completed |
| Фаза: | Phase 2 |
| Начало: | 31 мая 2019 г. |
| Окончание: | 28 сентября 2022 г. |
| Описание: | The primary objective of this study is to evaluate the efficacy of bulevirtide in combination with pegylated interferon in participants with chronic hepatitis delta (CHD). |
| смотреть на ClinicalTrials.gov |
| Статус: | Completed |
| Фаза: | Phase 3 |
| Начало: | 17 апреля 2019 г. |
| Окончание: | 8 августа 2024 г. |
| Описание: | The primary objective of this study is to evaluate the efficacy of bulevirtide for treatment of chronic hepatitis delta (CHD) in comparison to delayed treatment. All participants will undergo a further off-treatment follow-up period of 96 weeks. |
| смотреть на ClinicalTrials.gov |
| Статус: | Completed |
| Фаза: | Phase 2 |
| Начало: | 1 апреля 2016 г. |
| Окончание: | 30 октября 2020 г. |
| Описание: | Randomised, Comparative, Parallel-Arm Study to Assess Efficacy and Safety of Myrcludex B in Combination with Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients with Chronic Viral Hepatitis B with Delta-agent |
| смотреть на ClinicalTrials.gov |
| Статус: | Completed |
| Фаза: | Phase 2 |
| Начало: | 1 апреля 2016 г. |
| Окончание: | 30 октября 2020 г. |
| Описание: | Randomised, Comparative, Parallel-Arm Study to Assess Efficacy and Safety of Myrcludex B in Combination with Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients with Chronic Viral Hepatitis B with Delta-agent |
| смотреть на ClinicalTrials.gov |
| Статус: | Completed |
| Фаза: | Phase 1/Phase 2 |
| Начало: | 14 ноября 2012 г. |
| Окончание: | 4 октября 2014 г. |
| Описание: | A randomized, open-label multicentre clinical trial of daily Myrcludex B versus entecavir in patients with HBeAg negative chronic hepatitis B. |
| смотреть на ClinicalTrials.gov |